Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less
David F. Stroncek(Yale University), Michael A. Pulsipher(Primary Children's Hospital), Matthew D. Seftel(CancerCare Manitoba), Siddhartha Ganguly(University of Kansas Medical Center), Christopher Bredeson, Deidre M. Kiefer(National Marrow Donor Program), Galen E. Switzer(University of Pittsburgh), Kimberly A. Kasow(University of North Carolina at Chapel Hill), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nirali N. Shah(National Institutes of Health), Jeff Szer(The Royal Melbourne Hospital), Zheng Zhou(Ocean University of China), Ibrahim Ahmed(Children's Mercy Hospital), Bronwen E. Shaw(Royal Marsden NHS Foundation Trust), Amer Beitinjaneh(University of Miami), Peiman Hematti(UW Health University Hospital), Zachariah DeFilipp(Harvard University), Hillard Lazarus(University Hospitals Cleveland Medical Center), Sachiko Seo(National Cancer Center Hospital East), Paul V. O’Donnell(Johns Hopkins Hospital), Pashna N. Munshi(Johns Hopkins Hospital), Hisham Abdel‐Azim(University of Southern California), Richard F. Olsson(AstraZeneca (Netherlands)), Jane L. Liesveld(Strong Memorial Hospital), Dipnarine Maharaj, Paolo Anderlini(The University of Texas MD Anderson Cancer Center), Pintip Chitphakdithai(National Marrow Donor Program), Bipin N. Savani(Vanderbilt University Medical Center), Miguel Ángel Díaz(Hospital Infantil Universitario Niño Jesús), Joerg Halter(University Hospital of Basel), Jean A. Yared(University of Maryland, Baltimore), Gregory A. Hale(Johns Hopkins University), Dennis L. Confer(National Marrow Donor Program)
Cited by 7
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859